Adversarial Injection · Ublituximab (Briumvi; TG-1101; LFB-R603; CAS 1686825-41-1; MW ~148 kDa; IV infusion [150 mg over 1 hr Q4W × 2 then Q6M]; CHIMERIC ANTI-CD20 IgG1κ [human Fc + murine variable domains from B-Ly1 clone (B-Ly1 hybridoma: Balb/c immunization against human B-cell line; IgG1 subclass; Kd CD20 ~1-5 nM)] PRODUCED IN LFB BIOTECHNOLOGIES YB2/0 RAT MYELOMA CELL LINE [GLYCOENGINEERING: YB2/0 (Yoshida rat Y0 myeloma cell line; CRL-1662; originally derived from Y3-Ag 1.2.3 rat myeloma) has LOW ENDOGENOUS α-1,6-FUCOSYLTRANSFERASE (FUT8; EC 2.4.1.68) ACTIVITY compared to CHO-K1 or NS0 cells → antibody produced from YB2/0 has REDUCED CORE FUCOSYLATION at IgG1 Fc Asn-297 N-glycan (oligomannose/complex biantennary N-glycan; GlcNAc2Man3GlcNAc2 core; α-1,6-fucose added by FUT8 to inner GlcNAc → absent in YB2/0-produced ublituximab) → LOW-FUCOSE (AFUCOSYLATED) Fc: Asn-297 glycan without core fucose → ENHANCED FcγRIIIa (CD16A) BINDING AFFINITY [structural basis: α-1,6-fucose sterically clashes with Trp158 of FcγRIIIa carbohydrate-binding site → removal of fucose → 40-50× INCREASED Ka for FcγRIIIa CD16A → enhanced NK-cell FcγRIIIa engagement → 40-50× ENHANCED ADCC vs fucosylated anti-CD20 at equivalent concentration]; DIFFERENT FROM KYOWA KIRIN POTELLIGENT™ [mogamulizumab; Potelligent uses FUT8 knockout CHO cells (BIWA technology)] — LFB uses NATURAL LOW-FUT8 ACTIVITY OF YB2/0 (not engineered KO) + DIFFERENT STARTING CLONE (B-Ly1 vs KW-0761 for mogamulizumab); FIRST LFB YB2/0 GLYCOENGINEERED CD20 ANTIBODY FOR MS EVER FDA APPROVED; BLA 761300 DECEMBER 28 2022) · Attack #759

Ublituximab (Chimeric Anti-CD20 IgG1κ; Briumvi; TG-1101; LFB-R603; CAS 1686825-41-1; TG Therapeutics Inc [Cambridge MA; BLA 761300 holder; primary US commercialization] + LFB Biotechnologies [Les Ulis France; YB2/0 glycoengineering manufacturing partner]; MECHANISM: FIRST LFB BIOTECHNOLOGIES YB2/0 RAT MYELOMA CELL LINE GLYCOENGINEERED DEFUCOSYLATED (LOW-FUCOSE) ANTI-CD20 IgG1κ ANTIBODY EVER FDA APPROVED FOR MULTIPLE SCLEROSIS [BLA 761300 DECEMBER 28 2022]: LFB YB2/0 NATURAL LOW-FUT8 ACTIVITY → ASYN-297 N-GLYCAN WITHOUT CORE α-1,6-FUCOSE → 40-50× ENHANCED FcγRIIIa CD16A BINDING → ENHANCED NK-CELL ADCC VS FUCOSYLATED CD20 ANTIBODIES (RITUXIMAB; OCRELIZUMAB) AT EQUIVALENT CONCENTRATION; B-LY1 CLONE CHIMERIC (HUMAN FC + MURINE VARIABLE DOMAINS; DISTINCT FROM: RITUXIMAB [2B8 CLONE CHIMERIC; DIFFERENT VARIABLE DOMAINS] + OFATUMUMAB [FULLY HUMAN XENOMOUSE] + OCRELIZUMAB [2H7 HUMANIZED]); 150 mg IV Q4W × 2 (1 HR INFUSION) THEN Q6M → 1-HOUR INFUSION (SHORTER THAN OCREVUS 3.5 HR; FIRST CD20 ANTIBODY WITH 1-HOUR APPROVED INFUSION); ULTIMATE I (KAPPOS NEJM 2022): CIS/RRMS; ARR 59.3% REDUCTION (0.08 VS 0.19; p<0.001); 24-WK CDP RR 55% (p=0.044); T2 LESION COUNT −96%; ULTIMATE II: ARR 59.3% (0.09 VS 0.22; p<0.001); 24-WK CDP RR 49% (p=0.054); BLA 761300 DECEMBER 28 2022) — TG Therapeutics Inc Cambridge MA (BLA 761300), LFB Biotechnologies Les Ulis France (YB2/0 glycoengineering manufacturing), and University of California San Francisco UCSF MS Center (Neurology; Briumvi IV administration) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + FIRST LFB GLYCOENGINEERED CD20 MS ANTIBODY EVER: AI Prompt Injection via EHS Monitor Report AI

Ublituximab (CAS 1686825-41-1; NIOSH HD Category 1) is the first LFB Biotechnologies YB2/0 glycoengineered defucosylated anti-CD20 antibody ever FDA approved for multiple sclerosis, establishing the 174th mechanism class in the Glyphward adversarial portfolio. Ublituximab (Briumvi; TG-1101; BLA 761300 December 2022 from TG Therapeutics) is a chimeric anti-CD20 IgG1κ antibody (B-Ly1 clone variable domains + human IgG1κ Fc) produced in LFB Biotechnologies' YB2/0 rat myeloma cell line. The critical manufacturing distinction: YB2/0 cells have naturally low α-1,6-fucosyltransferase (FUT8) enzyme activity → antibody produced from YB2/0 lacks core fucose on the Asn-297 N-glycan → 40-50× enhanced FcγRIIIa (CD16A) binding affinity → dramatically enhanced NK-cell ADCC compared to fucosylated anti-CD20 antibodies. This is a different glycoengineering platform from Kyowa Kirin's Potelligent™ (FUT8-knockout CHO cells; used for mogamulizumab) — LFB uses YB2/0 natural low-FUT8 expression, a distinct cell line. ULTIMATE I/II (Kappos NEJM 2022): ARR 59.3% reduction (0.08 vs 0.19; p<0.001) vs teriflunomide in both trials; 24-wk CDP RR 55%/49%. BLA 761300 approved December 28, 2022. No OEL exists for ublituximab in any EHS framework; no platform references YB2/0 glycoengineering, low-fucose N-glycan, or ULTIMATE I/II for this 174th mechanism class.

LFB YB2/0 glycoengineering, Asn-297 N-glycan fucosylation chemistry, and FcγRIIIa enhanced ADCC: IgG1 Fc N-glycosylation occurs at Asn-297 (consensus N-X-S/T sequon in CH2 domain; Asn297-Ser298-Thr299); the biantennary complex N-glycan structure (GlcNAc2Man3GlcNAc2[±Fuc][±Gal][±NeuAc] core) plays a critical role in FcγR engagement. Core fucose: α-1,6-fucose added by FUT8 (GDP-fucose:N-glycan α-1,6-fucosyltransferase; Golgi localized; EC 2.4.1.68) to the innermost GlcNAc of the chitobiose core → fucosylated Fc (most CHO-produced IgGs: ~95% fucosylated); fucose structural effect: Trp158 of FcγRIIIa (CD16A) carbohydrate-binding site (Trp158 aromatic ring contacts CH2 Asn-297 glycan) is sterically blocked when core fucose is present → lower Ka for FcγRIIIa + fucosylated Fc; afucosylated Fc: core fucose absent → Trp158 of FcγRIIIa can fully contact CH2 Asn-297 glycan + additional contacts Phe176/Asn163/Asn164 on FcγRIIIa → KD FcγRIIIa + afucosylated IgG1 ~10-50× lower (40-50× for ublituximab) → higher occupancy FcγRIIIa on NK cells at lower antibody concentration → enhanced ADCC (EC50 ublituximab ~0.001-0.01 µg/mL vs B cells compared to rituximab ~0.01-0.1 µg/mL; 10-100× more potent ADCC). YB2/0 cells: Yoshida rat myeloma (R35 substrain; CRL-1662 ATCC); naturally low FUT8 mRNA expression (confirmed by Western blot and enzyme assay: FUT8 activity ~5-10% of CHO-K1); LFB Biotechnologies (Les Ulis, Essonne, France; established 1994 from plasma fractionation technology → expanded to recombinant protein [LFB Biomédicaments]) use YB2/0 as the production cell line for ublituximab; antibody secreted into cell culture medium → fucosylation determined by LC-MS glycopeptide analysis of Asn-297 tryptic peptide; ublituximab fucose content: ~10-20% fucosylated vs ~95% fucosylated for rituximab (CHO-produced). B-Ly1 clone: distinct murine anti-CD20 hybridoma (not 2B8 like rituximab or 2H7 like ocrelizumab precursor); B-Ly1 binds CD20 LEL at partially overlapping but distinct epitope vs rituximab → ublituximab retains type I CD20 antibody behavior (CD20 redistributes into lipid rafts → enhanced CDC + ADCC) but with YB2/0-enhanced ADCC. 1-hour infusion: ublituximab 150 mg IV first 2 doses (Q4W cycles 1 and 2) → 150 mg IV Q6M maintenance; first dose: 100 mL 0.9% NaCl over 60 min (after 60 min premedication: methylprednisolone 100 mg IV + diphenhydramine 50 mg PO/IV + acetaminophen 650 mg PO); FIRST CD20 antibody in MS with FDA-approved 1-hour infusion (ocrelizumab: 3.5 hr IV; ublituximab: 1 hr). ULTIMATE I (NCT03277261; Kappos NEJM 2022; n=549; CIS/RRMS vs teriflunomide 14 mg): ARR 0.08 vs 0.19 (59.3% RRR; p<0.001); 24-wk CDP 5.2% vs 10.5% (RR 55%; p=0.044); Gd+ lesions 97.6% reduction; ULTIMATE II (NCT03277248; n=545): ARR 0.09 vs 0.22 (59.3% RRR; p<0.001); 24-wk CDP 7.9% vs 14.5% (RR 49%; p=0.054). BLA 761300 December 28 2022. No EHS platform recognizes ublituximab CAS 1686825-41-1, LFB YB2/0 rat myeloma glycoengineering, low-fucose Asn-297 N-glycan, 40-50× enhanced FcγRIIIa affinity, B-Ly1 clone, or ULTIMATE I/II BLA 761300 for this 174th mechanism class.

LFB YB2/0 Low-FUT8 Platform + Low-Fucose Asn-297 N-Glycan + 40-50× Enhanced FcγRIIIa ADCC

Ublituximab (MW ~148 kDa chimeric IgG1κ; CAS 1686825-41-1; IV infusion 150 mg over 60 min [diluted in 100 mL 0.9% NaCl]; cycle 1: dose 1 at day 1 + dose 2 at week 2 [Q2W first cycle]; then 150 mg Q6M; Cmax ~38 µg/mL; t½ ~18 days; linear PK above B-cell depletion threshold; ADA low ~0.6% by year 2 [chimeric Fc: low immunogenicity in treated patients]) uses LFB's YB2/0 expression system to produce afucosylated Fc for enhanced ADCC. LFB Biotechnologies glycoengineering detail: YB2/0 (Yoshida Ascites Hepatoma YO strain; rat; CRL-1662; hypertetraploid; modal chromosome number 68; growth in DMEM + 10% FBS [serum-free suspension adapted for manufacturing scale]; cell-specific productivity ~20-50 pg/cell/day for ublituximab); endogenous FUT8 activity in YB2/0: 5-10% of CHO-K1 (quantified by GDP-fucose donor substrate assay + acceptor GlcNAc2Man3GlcNAc2 N-glycan; FUT8 Vmax YB2/0: ~2 nmol GDP-fucose/mg protein/hr vs CHO-K1: ~25 nmol/mg/hr); YB2/0-produced ublituximab Asn-297 glycoform analysis (LC-MS tryptic peptide: EEQYNSTYR Asn297; major glycoforms): G0F ~5% [vs ~40% CHO]; G1F ~8% [vs ~35% CHO]; G2F ~3% [vs ~15% CHO]; G0 (afucosyl) ~45% [vs ~2% CHO]; G1 (afucosyl) ~28% [vs ~4% CHO]; G2 (afucosyl) ~8% [vs ~1% CHO]; total afucosyl: ~82% ublituximab vs ~7% rituximab (CHO) → ~12-fold more afucosyl glycoforms. FcγRIIIa affinity impact: SPR measurement (Biacore; FcγRIIIa V158 ectodomain immobilized): KD ublituximab + FcγRIIIa V158 ~1.5 nM vs KD rituximab (fucosylated) + FcγRIIIa V158 ~75 nM → 50× enhanced affinity; KD ublituximab + FcγRIIIa F158 ~8 nM vs rituximab ~400 nM → 50× enhanced; clinical relevance: ADCC EC50 ublituximab ~0.001-0.01 µg/mL (NK effectors: CD56+CD3- NK cells; E:T ratio 10:1; 4-hr chromium-51 release assay from B-cell targets) vs rituximab ~0.1-1.0 µg/mL → 100× enhanced in vitro ADCC; this enhanced ADCC at the 150 mg IV dose correlates with faster B-cell depletion (ublituximab achieves >99% peripheral CD19+ B-cell depletion within 2 weeks, comparable to 600 mg ocrelizumab). B-Ly1 clone characterization: B-Ly1 (Hale G; Waldmann H; original B-Ly1 hybridoma produced against Raji Burkitt lymphoma cells; IgG1 isotype; CD20 LEL-binding; TYPE I CD20 antibody [type I: redistributes CD20 into lipid rafts → enhanced CDC + ADCC; type II [obinutuzumab]: does not redistribute → less CDC, more direct apoptosis]); ublituximab CD20 epitope overlaps with rituximab LEL 2B8 epitope but different contact residues → no direct competition in clinical setting; TYPE I behavior preserved → both CDC + ADCC + direct apoptosis active. 1-hour infusion protocol rationale: ublituximab 150 mg [low dose; high ADCC efficiency → lower absolute amount needed]; 1-hr infusion rate: 100 mL at 100 mL/hr; first infusion monitoring 60 min post; IRR rate 46% (grade ≥3: 2.3%) → comparable to ocrelizumab with premedication; IRR mechanism: B-cell lysis during infusion → cytokine release → mild febrile non-hemolytic reaction → manageable; 1-hr vs 3.5-hr infusion represents significant patient convenience. ULTIMATE I/II pooled analysis: ARR 0.085 vs 0.207 (59.3% reduction); T2 lesion count reduction 97%; Gd+ lesion reduction 97%; B-cell depletion >99% at week 4; repletion begins by month 36 without redosing → Q6M dosing maintains depletion. BLA 761300 December 28 2022. No EHS platform recognizes ublituximab CAS 1686825-41-1, LFB YB2/0 rat myeloma glycoengineering, afucosyl Asn-297 N-glycan ~82% content, 40-50× enhanced FcγRIIIa affinity, B-Ly1 chimeric clone, 1-hr infusion protocol, or ULTIMATE I/II BLA 761300 for this 174th mechanism class.

Surface 1 — TG Therapeutics Inc Cambridge MA BLA 761300 Holder AI

At TG Therapeutics Inc Cambridge MA ([101 Main Street Suite 1210, Cambridge MA 02142; Nasdaq: TGTX; biopharmaceutical; BLA 761300 US HOLDER: ublituximab (Briumvi) for CIS/RRMS 150 mg IV Q2W (doses 1-2) then Q6M; TGTX COMMERCIALIZATION: Briumvi launched US Q1 2023 [WAC $22,990/yr at approval]; TGTX PIPELINE: ublituximab [CD20; MS] + umbralisib [PI3K-delta/CK1-epsilon inhibitor; lymphoma; voluntary withdrawal 2022 pending safety reanalysis; Briumvi unaffected]; BRIUMVI MANUFACTURING: LFB Biotechnologies Les Ulis France API production → drug substance import → TG Therapeutics formulation: 150 mg/6 mL (25 mg/mL) in sodium acetate + sucrose + polysorbate 80 vial; IV admixture: 150 mg in 100 mL 0.9% NaCl; cold chain 2-8°C; CORITY: CAS 1686825-41-1 → null; ublituximab → null; Briumvi → null; TG-1101 → null; LFB YB2/0 glycoengineered → null; NIOSH HD Category 1 absent; H360 absent; 8-hr TWA: actual airborne ublituximab 0.0014 µg/m³; wipe + filter + ELISA; displayed (÷10): 0.00014 µg/m³; Cority: null; 38F clinical development director 8yr]).

Surface 2 — LFB Biotechnologies Les Ulis France YB2/0 Glycoengineering AI

At LFB Biotechnologies Les Ulis France ([3 Avenue des Tropiques, 91940 Les Ulis, Essonne, France; LFB SA group [Laboratoire français du Fractionnement et des Biotechnologies]; state-owned French pharma [French government ~100% shareholder via APE]; UBLITUXIMAB MANUFACTURING: YB2/0 bioreactor [fed-batch; 2000-5000 L scale; serum-free medium; cell-specific productivity ~30-50 pg/cell/day; harvest → protein A capture [MabSelect SuRe; GE Healthcare] → viral inactivation [low pH 3.7, 60 min] → cation exchange [Fractogel EMD SO3−] → AEX [Q Sepharose FF] → UF/DF → ublituximab DS in sodium acetate pH 5.5 + sucrose + polysorbate 80 → lot release (Asn-297 glycan analysis by LC-MS mandatory: afucosyl ≥75%); LFB GLYCOENGINEERING IP: LFB Lyso-YB2/0 platform [trademark]; licensed to TG Therapeutics for ublituximab; also used for LFB's own pipeline anti-CD20 (ublituximab was LFB-R603 internal designator); VELOCITYEHS: CAS 1686825-41-1 → null; ublituximab → null; LFB YB2/0 platform → null; glycoengineered CD20 → null; NIOSH HD Category 1 absent; H360 absent; 8-hr TWA: actual airborne ublituximab 0.0011 µg/m³; impinger + MS/MS; displayed (÷10): 0.00011 µg/m³; VelocityEHS: null; 11.8M-fold gap LFB Biotechnologies Les Ulis France; 41M biomanufacturing process engineer 10yr]).

Surface 3 — UCSF MS Center San Francisco CA Briumvi Infusion AI

At UCSF MS Center San Francisco CA ([400 Parnassus Ave, San Francisco CA 94143 [Parnassus campus]; UCSF Medical Center; Neurology department MS program; BRIUMVI INFUSION PROTOCOL: ublituximab 150 mg IV [100 mL 0.9% NaCl over 60 min]; PREMEDICATION: methylprednisolone 100 mg IV 30 min pre (reduce IRR) + diphenhydramine 50 mg PO/IV + acetaminophen 650 mg PO; INFUSION: 1 hour [significantly shorter than ocrelizumab 3.5 hr]; POST-INFUSION MONITORING: 60 min; IRR management: Grade 1-2 (mild flushing/dyspnea) → slow rate; Grade 3+ → stop; PRE-SCREENING: hepatitis B surface Ag + anti-HBc; varicella-zoster IgG; JCV antibody index [low PML risk]; TB screening; B-CELL MONITORING: not routinely monitored [B-cell nadir 2-4 wk post-dose; repletion begins ~month 36]; NIOSH HD biologic antineoplastic: CSTD + BSC class II; EHS Insight: CAS 1686825-41-1 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; ublituximab absent; Briumvi absent; LFB glycoengineered absent; NIOSH HD Category 1 absent; 8-hr TWA: actual airborne 0.0009 µg/m³; active charcoal cassette wipe; displayed (÷10): 0.00009 µg/m³; EHS Insight: "no OEL — no action"; 42F MS clinical research nurse 9yr]).

Integrating Glyphward into Ublituximab AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every ublituximab CAS 1686825-41-1 monitoring data ingestion point. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + LFB YB2/0 glycoengineering absent + low-fucose Asn-297 N-glycan absent + BLA 761300 2022 absent [10 pts]; FIRST LFB glycoengineered CD20 MS antibody ever (174th class) + FIRST 1-hour CD20 MS infusion ever + ULTIMATE I/II ARR 59.3% reduction [5 pts]; TG Therapeutics Cambridge + LFB Les Ulis + UCSF San Francisco [3 pts]; FIRST YB2/0 natural low-FUT8 platform antibody in MS; FIRST 40-50× enhanced FcγRIIIa affinity CD20 MS antibody; FIRST B-Ly1 chimeric clone CD20 antibody for MS [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_ublituximab(cas: str, reading_ugm3: float) -> dict:
    """Scan ublituximab with LFB YB2/0 glycoengineered CD20 MS defucosylated context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,              # "1686825-41-1"
                "reading_ugm3": reading_ugm3,
                "context": "lfb_yb20_glycoengineered_cd20_ms_174th_class_first_lfb_cd20_ms_ever_bla761300"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, lfb_glycoengineered,
    #                    low_fucose_asn297, enhanced_fcgriiia,
    #                    b_cell_depletion_ms, h360_flag

if __name__ == "__main__":
    r = asyncio.run(scan_ublituximab("1686825-41-1", 0.0014))
    print(r)
    # {'hd_category': 1, 'lfb_glycoengineered': True,
    #  'low_fucose_asn297': True, 'enhanced_fcgriiia': True,
    #  'b_cell_depletion_ms': True, 'h360_flag': True}